Published in Lab Invest on July 25, 2016
Oxidative Stress-Related Mechanisms and Antioxidant Therapy in Diabetic Retinopathy. Oxid Med Cell Longev (2017) 0.77
The Role of DNA Methylation in the Metabolic Memory Phenomenon Associated With the Continued Progression of Diabetic Retinopathy. Invest Ophthalmol Vis Sci (2016) 0.75
Peripheral Blood Mitochondrial DNA Damage as a Potential Noninvasive Biomarker of Diabetic Retinopathy. Invest Ophthalmol Vis Sci (2016) 0.75
Novel insights into DNA methylation and its critical implications in diabetic vascular complications. Biosci Rep (2017) 0.75
Epigenetic Regulation of Redox Signaling in Diabetic Retinopathy: Role of Nrf2. Free Radic Biol Med (2016) 0.75
Role of oxidative stress in epigenetic modification of MMP-9 promoter in the development of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets. Cell Biosci (2017) 0.75
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
CpG islands and the regulation of transcription. Genes Dev (2011) 9.50
TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature (2011) 8.31
DNA methylation in health and disease. Nat Rev Genet (2000) 4.58
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
TET enzymes, TDG and the dynamics of DNA demethylation. Nature (2013) 3.49
Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell (2014) 3.17
Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes (2009) 2.96
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene (2012) 2.82
Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci (2007) 2.28
Diabetes-induced mitochondrial dysfunction in the retina. Invest Ophthalmol Vis Sci (2003) 2.07
Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci (2000) 2.06
Parp inhibition prevents ten-eleven translocase enzyme activation and hyperglycemia-induced DNA demethylation. Diabetes (2014) 1.52
Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy. Invest Ophthalmol Vis Sci (2014) 1.52
Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol (2010) 1.51
Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes (2011) 1.32
Epigenetics: deciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol (2011) 1.17
Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol (2014) 1.15
Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes (2013) 1.14
Intergenic, gene terminal, and intragenic CpG islands in the human genome. BMC Genomics (2010) 1.13
Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs (2012) 1.10
Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res (2015) 1.05
Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes (2012) 1.04
Dynamic regulation of DNA methylation during mammalian development. Epigenomics (2009) 1.01
Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun (2002) 0.99
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Epigenetic modifications and diabetic retinopathy. Biomed Res Int (2013) 0.97
Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression. Curr Med Chem (2013) 0.96
Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. Invest Ophthalmol Vis Sci (2012) 0.96
Distinct nuclear localization patterns of DNA methyltransferases in developing and mature mammalian retina. J Comp Neurol (2011) 0.95
Review: Epigenetic mechanisms in ocular disease. Mol Vis (2013) 0.91
Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-κB and AP-1 activity in human liver cancer cells. Br J Pharmacol (2014) 0.88
Epigenetic Modification of Mitochondrial DNA in the Development of Diabetic Retinopathy. Invest Ophthalmol Vis Sci (2015) 0.87
5-Hydroxymethylcytosine and disease. Mutat Res Rev Mutat Res (2014) 0.85
Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy. Biochem Biophys Res Commun (2013) 0.84
Epigenetics and cell death: DNA hypermethylation in programmed retinal cell death. PLoS One (2013) 0.83
Epigenetics and ocular diseases: from basic biology to clinical study. J Cell Physiol (2014) 0.83
The role of epigenetics in age-related macular degeneration. Eye (Lond) (2014) 0.81
Promoter DNA demethylation of Keap1 gene in diabetic cardiomyopathy. Int J Clin Exp Pathol (2014) 0.80
Molecular Mechanism of Transcriptional Regulation of Matrix Metalloproteinase-9 in Diabetic Retinopathy. J Cell Physiol (2015) 0.80
TET Family of Dioxygenases: Crucial Roles and Underlying Mechanisms. Cytogenet Genome Res (2015) 0.79
Role of site-specific DNA demethylation in TNFα-induced MMP9 expression in keratinocytes. J Mol Endocrinol (2013) 0.78